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Graphical Abstract. The potential of bio-enabling lipid vehicles, administered via chase 
dosing and lipid suspensions, has been evaluated as an approach to enhance oral 
bioavailability of nilotinib. 
 
Abstract  
Purpose Lipid-based formulations (LBF) have shown oral bioavailability enhancement of 
lipophilic drugs, but not necessarily in the case of hydrophobic drugs. This study explored the 
potential of lipid vehicles to improve the bioavailability of the hydrophobic drug nilotinib 
comparing a chase dosing approach and lipid suspensions. 
Methods Nilotinib in vivo bioavailability in rats was determined after administering an 
aqueous suspension chase dosed with blank olive oil, Captex 1000, Peceol or Capmul MCM, 
respectively. Absolute bioavailability was determined (relative to an intravenous formulation). 
Pharmacokinetic parameters were compared to lipid suspensions. 
Results Compared to the lipid suspensions, the chase dosed lipids showed a 2- to 7-fold higher 
bioavailability. Both long chain chase dosed excipients also significantly increased the 
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bioavailability up to 2-fold compared to the aqueous suspension. Deconvolution of the 
pharmacokinetic data indicated that chase dosing of nilotinib resulted in prolonged absorption 
compared to the aqueous suspension.  
Conclusion Chase dosed LBF enhanced the in vivo bioavailability of nilotinib. Long chain 
lipids showed superior performance compared to medium chain lipids. Chase dosing appeared 
to prolong the absorption phase of the drug. Therefore, chase dosing of LBF is favourable 
compared to lipid suspensions for ‘brick dust’ molecules such as nilotinib. 
 
Keywords Chase dosing, Lipid suspension, Lipid based formulation, Brick dust molecule, 
poorly water-soluble drugs 
 
Abbreviations: MC: medium chain; LC: long chain; MG: monoglyceride; TG: triglyceride; 




The oral bioavailability of many poorly water-soluble drugs is hindered by low solubility and 
slow dissolution in the gastrointestinal tract fluids. Lipid based formulations (LBF) are one 
option to improve the oral bioavailability of poorly water-soluble drugs and have shown 
numerous commercial success (1, 2). In particular, drugs in the Biopharmaceutical 
Classification System (BCS) class II and IV can benefit from usage of lipid excipients to 
enhance oral delivery. One of the primary biopharmaceutical advantages of LBFs is the ability 
to deliver the drug dissolved in lipid excipients and therefore avoiding the drug dissolution 
process. In addition, LBFs have been shown to increase drug solubilisation within the intestinal 
fluids, as well as intestinal permeability and promoting intestinal lymphatic uptake (3, 4). To 
date, the majority of successful examples of enhanced in vivo bioavailability via a LBF 
approach have been demonstrated for poorly water-soluble drugs with highly lipophilic 
characteristics (i.e. high logP). Such drugs tend to display high solubility in lipid excipients 
which supports high dose loading in LBFs. However, poor solubility in water is not always 
reflective of a good solubility in lipid vehicles. Solubility in lipid vehicles can be solid state 
limited due to a strong crystal lattice, i.e. so called ‘brick dust’ molecules. For example, it has 
been reported that poorly water-soluble drugs with a melting point > 150 °C display an 
insufficient solubility in glycerides (5), and hence lipid vehicles, which limits the 
aforementioned advantage in terms of bypassing drug dissolution via a LBF. However, for 
‘brick dust’ drugs displaying both hydrophobic and high lipophilic properties it remains unclear 
whether the additional bio-enabling effects of lipid excipients can increase oral bioavailability. 
For such challenging compounds exhibiting low aqueous and lipid solubility the formulation 
as LBF is often disregarded. Recently, formulation strategies such as designing lipophilic salts 
or supersaturated LBFs have been proposed as an approach to increase the drug loading in a 
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LBF solution (6, 7). However, LBF suspensions (8, 9) and concomitant administration of drug 
and LBF excipients (chase dosing) (10, 11) have also shown promise in terms of enhancing the 
in vivo exposure. In the latter chase dosing, crystalline drug and the lipid excipient (or LBF) 
are administered immediately following each other. This can be done ad hoc via gavaging in 
rodents an aqueous suspension followed by the drug-free lipid vehicle or as a capsule-in-
capsule approach in humans or larger animals. Lipid and aqueous suspensions are particularly 
useful in a pre-clinical setting, offering a balance in terms of ease of administration in rodent 
models, and also the potential of the lipid excipient to increase in vivo exposure which is a key 
consideration for example in the early stage of toxicological drug evaluation. This is 
particularly relevant, as large resource investment in formulation design and optimisation in 
pre-clinical development is risky given the high attrition rate of drug candidates.  
 
Lipid suspensions have shown potential to enhance oral bioavailability for a number of poorly 
water-soluble drugs including danazol, fenofibrate and griseofulvin (8, 9, 12, 13). For example, 
in the case of danazol, a bioavailability increase of 4-9-fold was observed when dosed in a 
Labrafil M2125CS suspension compared to an aqueous suspension (8). However, in the case 
of ‘brick dust’ drugs like atovaquone and nilotinib, lipid excipients did not improve the 
bioavailability (14, 15). Atovaquone shows a positive food effect, high lipophilicity, high 
hydrophobicity and has a limited solubility in medium chain (MC) triglycerides (TG)  
of ⁓ 4 mg/mL. The bioavailability of an atovaquone MC TG suspension was similar to the 
bioavailability of an aqueous suspension in humans (15). In the case of nilotinib, which is 
highly lipophilic and hydrophobic with a MC TG solubility of ⁓ 0.05 mg/mL and a food effect 
of approximately 80 % (increase in AUC after a high fat meal), a similar bioavailability for 
both MC and long chain (LC) monoglyceride (MG) suspensions was observed. Interestingly, 
for nilotinib there was a significantly reduced bioavailability observed in case of both MC and 
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LC TG suspensions compared to an aqueous suspension (14). In the latter study, it was 
hypothesized that the main factor for the poor in vivo performance of the lipid suspensions was 
a kind of entrapment of the nilotinib drug crystal by a persistent lipid film due to a low 
dispersibility of the TGs. Such an entrapment may have hampered the drug interactions with 
the post digestive colloids in the gastrointestinal tract and hence drug solubilisation. 
Consequently, it was suggested that the separation of the drug and the lipid excipient would 
avoid such entrapment. The current study was hence designed to assess whether the 
concomitant administration of nilotinib as an aqueous suspension and a drug free LBF (chase 
dosing) would influence oral bioavailability relative to administration of either an aqueous or 
lipid-based drug suspension. 
 
Lipid co-administration or chase dosing has been shown to successfully enhance the 
bioavailability compared to an aqueous suspension or even lipid solution across different 
preclinical species and in humans (10, 11, 16). Additionally, co-administration avoids any risk 
of formulation or active pharmaceutical ingredient instability. Larsen et al. demonstrated in 
rats that for danazol, halofantrine and cinnarizine a co-administered lipid resulted in a similar 
bioavailability compared to a lipid solution, which was higher than the bioavailability of an 
aqueous suspension (10). In humans the co-administration of the commercial cinnarizine 
tablets with a placebo-LBF was tested in the fasted and fed state (11). In the fasted state the co-
administration showed a tendency to increase the bioavailability compared to the 
commercialized tablets. In the fed state a decreased food effect was observed based on the 
individual profiles (11). In a different study the co-administration of carvedilol was studied in 
dogs (16). Co-administering carvedilol with a drug-free-LBF showed a similar bioavailability 





Given that most research on LBFs is focused on a relatively limited number of model poorly 
water-soluble drugs, there is a need to study other more recently licenced drugs, such as the 
tyrosine kinase inhibitor nilotinib. Nilotinib is considered a ‘brick dust’ molecule based on its 
high lipophilicity (logP 4.95) and high melting point of 236 ⁰C and hence displays low 
solubility in lipid excipients. The present study investigated the hypothesis that nilotinib would 
benefit from co-administration with lipids rather than its direct formulation as a lipid 
suspension. To compare the results of the previously published lipid suspensions to the present 
chase dosing approach, the previously tested lipid excipients olive oil (LC TG), Captex 1000 
(MC TG), Peceol (LC MG) and Capmul MCM (MC MG) were also evaluated in vivo.  
 
2 Materials and methods 
2.1 Chemicals and materials 
Nilotinib and sorafenib were purchased from Kemprotec Ltd. (UK). Olive oil (LC TG), highly 
refined and low acidity was obtained from Sigma-Aldrich (Ireland). Capmul MCM® (MC MG) 
and Captex 1000® (MC TG) were kindly donated by Abitec corporation (USA). A sample of 
Peceol® (LC MG) was kindly donated by Gattefossé (France). All other chemicals and solvents 
were of analytical or high-performance liquid chromatography (HPLC) grade and were 
purchased from Sigma-Aldrich (Ireland) and used as received. 
 
2.2 Formulations for in vivo studies 
For the lipid co-administration, an aqueous suspension with 20 mg/mL nilotinib was prepared 
by adding 20 mg nilotinib to 1 mL of the aqueous 0.5 % (w/v) methylcellulose solution and 
mixed thoroughly. To decrease any powder aggregates, the suspension was placed in an 
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ultrasonic bath for 5 sec and vortexed again afterwards. For the lipid suspensions the lipid 
excipients were melted as needed and 10 mg/mL nilotinib was added and stirred overnight. To 
ensure a homogeneous distribution of nilotinib, all suspensions were stirred prior to 
administration.  
 
The intravenous formulation was prepared by adding 2.5 mL Cremophor EL to 7.5 mL water 
for injection. The pH was adjusted to 2.0 and 0.5 mg/mL nilotinib was added to the solution 
and stirred until dissolved.  
 
2.3 In vivo study 
The protocol used for the in vivo pharmacokinetic study was approved by the institutional 
animal ethics committee in accordance with Belgian law regulating experiments on animals 
and in compliance with EC directive 2010/63/EU and the NIH guidelines on animal welfare. 
Male Sprague-Dawley rats weighing 250-320 g on the day of the experiments were purchased 
from Charles River Laboratories Deutschland (Sulzfeld, Germany) and maintained on standard 
food and water ad libitum in the laboratory for at least 5 days before entering the experiment. 
Food was removed 16-20 h before dosing and water was available ad libitum at all times. For 
the oral study arms, parallel groups of animals were administered an aqueous suspension at a 
volume of 1 mL/kg by oral gavage with a nilotinib dose of 20 mg/kg immediately followed by 
oral administration of the drug free lipid excipient at a volume of 2 mL/kg. For the intravenous 
part, animals were slowly injected 5 mL/kg of the intravenous formulation (2.5 mg/kg nilotinib) 
via the tail vein. 200 µL blood samples were collected into plasma collection tubes containing 
dipotassium EDTA by individual tail vein puncture. Samples were taken at 0.5, 1, 2, 4, 6, 8, 10 
and 24 h following oral dosing and at 0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h following intravenous 
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dosing. Plasma was harvested immediately by centrifugation for 10 min at 4 °C and 1,900  g 
and stored at -20 °C until analysis. After the experiment the animals were euthanized. 
 
2.4 Bioanalysis 
The plasma concentrations of nilotinib were determined by reversed phase HPLC. The Agilent 
1260 series HPLC system comprised a binary pump, degasser, temperature controlled 
autosampler, column oven and diode array detector. The system was controlled, and the data 
analysed with EZChrom Elite version 3.3.2. The employed method was described previously 
(14). In brief, a Zorbax Eclipse Plus-C18 column (5 μm, 4.6 mm x 150 mm) with a Zorbax 
Eclipse Plus-C18 guard column (5 μm, 4.6 mm x 12.5 mm) was used. The mobile phase 
consisted of water, methanol, acetonitrile and triethylamine (34:30:35:1 v/v) and was used at a 
flow rate of 0.9 mL/min. The sample and column temperature were set at 5 °C and 25 °C, 
respectively, and the detection wavelength was 267 nm. Nilotinib was extracted from the 
plasma samples by liquid-liquid extraction. To 50 μL of the plasma sample 66 μL of a methanol 
acetonitrile mixture (30:35 v/v), containing 1.25 μg/mL sorafenib as internal standard, was 
added. The mixture was mixed thoroughly and centrifuged at 22 °C, 11,500 x g for 9 min.  
50 μL of the supernatant was injected to the HPLC system for analysis. The lower limit of 
detection (LOD) and lower limit of quantification (LOQ) in plasma by this method was  
11 ng/mL and 37 ng/mL, respectively, determined using the standard error of y-intercept 
according to ICH Q2 (17). Linearity was confirmed between 37 ng/mL and 4.1 μg/mL.  
 
2.5 Deconvolution 
Concentration-time-profiles were deconvoluted to obtain information about the absorption 
process as a in vivo absorption function over time. This was done in Microsoft Excel by means 
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of system analysis and required no compartmental pharmacokinetic modelling or curve fitting 
(18, 19). The response observed after oral administration of nilotinib, i.e. the plasma 
concentration time profile, can be treated as the response function R(t). Additionally, a 
weighting function W(t) is needed, which can be obtained from intravenous or oral bolus 
administration. The correlation between both functions R(t) and W(t) depends on the input and 
can be described by the following integral (18, 19): 




where R, I and W are the response, input and weighing function, respectively. In this study, the 
weighing and response functions were known from the oral and intravenous plasma 
concentration profiles. The input function combines the information about the release and 
absorption process and was sought. The integral is also known as the convolution integral and 
can be written as follows: 
𝑅(𝑡) = 𝐼(𝑡) ∗ 𝑊(𝑡) 
where * is the convolution operator. The process to obtain I(t) is called deconvolution and was 










where T is the time interval, I (xk) the average input rate and W(xk) the weight between the 
times Xk-1 and Xk. Considering the sample time intervals, W(T) can be calculated as follows: 
𝑊(𝑇) = 𝑒(𝑚∗𝑇+𝑛) 
where T is the time interval (t2-t1), m the slope of the intravenous data and n the intercept of 







where I(t) is the sought deconvolved input function. The amount of drug released and absorbed 
is the cumulative input curve, i.e. the sum of I(t) up to every time point. This amount can be 
converted to % by setting the sum of all I(t) equal to 100 % drug absorbed. In this study the 
total absorbed amount was set equal to 100 % as well as the absolute bioavailability (Fabs) in 
order to obtain information about the extent and kinetics of the absorption process at the same 
time. Therefore, the % drug released and absorbed was calculated as follows: 
% 𝑑𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑎𝑛𝑑 𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑 =







2.6 Data Analysis 
The pharmacokinetic parameters were calculated using Microsoft Excel. The plasma 
concentration profiles were analysed by non-compartmental analysis and calculation of each 
area under the curve (AUC) was based on the linear trapezoidal rule. 
 
The statistical analysis was performed using a one-way analysis of variance (one-way 
ANOVA) after using the Bartlett’s test to check for equal variance. The pairwise comparison 
of the groups was done using Tukey’s multiple comparison test. All statistical analyses were 
based on GraphPad Prism 5. 
 
3 Results 
3.1 Long chain lipid-based formulations increased bioavailability of nilotinib 
Nilotinib was orally dosed as an aqueous suspension followed by oral administration of the 
pure lipid excipients olive oil (LC TG), Captex 1000 (MC TG), Peceol (LC MG) or Capmul 
MCM (MC MG). Additionally, an intravenous formulation was administered to allow absolute 
bioavailability to be determined. The mean plasma concentration versus time profiles (after 
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oral administration) are presented in Figure 1 together with the relative bioavailability (Frel) 
compared to the aqueous suspension. The mean plasma versus time profile for the intravenous 
formulation are shown in Figure 2. Table 1 presents a summary of the pharmacokinetic 
parameters obtained for all dosed formulations.  
 
 
Fig. 1. A: Plasma concentration profiles as a function of time (mean ± SD, n = 5) for nilotinib 
aqueous suspension with a dose of 20 mg/kg co-administered with LC MG [Peceol] (●),  
LC TG [Olive oil] (■), MC MG [Capmul MCM] (▲) and MC TG [Captex 1000] (▽) in male 
Sprague-Dawley rats. Additionally, a nilotinib aqueous suspension (♦) with 20 mg/kg 
nilotinib in the same species previously reported (14) (mean ± SD, n = 5). B: Relative 
bioavailability of co-administered lipid excipients compared to the aqueous suspension 
previously published (14) 
 
Co-administration of LC based LBFs resulted in a significant increase in nilotinib 
bioavailability relative to that obtained for an aqueous suspension alone (p ≤ 0.05). The highest 
relative bioavailability was observed for the LC MG formulation (191 ± 22 %) followed by the 
LC TG vehicle (171 ± 39 %). Additionally, LC MG showed the highest cmax with  
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4.12 ± 0.67 µg/mL and the lowest variability for AUC and cmax. In the case of the MC 
formulations, a relative bioavailability of 131 ± 42 % for MC TG and 106 ± 42 % for MC MG 
was observed, which were not statistically different to the aqueous nilotinib suspension alone.  
 
 
Fig. 2. Plasma concentration profiles as a function of time for an intravenous nilotinib 
formulation dosed at 2.5 mg/kg in male Sprague-Dawley rats (mean ± SD, n = 6). 
 
Among the various lipid formulations evaluated, while there was a trend towards a lower 
bioavailability for the MC TG excipient, only the MC MG was significantly lower compared 
to LC MG (p ≤ 0.05). The general ranking among the four formulations was LC MG ≥ LC TG 
≥ MC TG ≥ MC MG. These results indicated that LC excipients performed better than MC 
excipients, which may be related to a long chain fatty acid mediated increase in bile salt release 
(20-22). Additionally, the results showed that in vivo exposure was not influenced by whether 
the LBF was administered as either a MG or a TG, when chase dosed.  
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Table I Pharmacokinetic parameters of an orally nilotinib aqueous suspension chase dosed with olive oil (LC TG), Captex 1000 (MC TG), 
Peceol (LC MG) and Capmul MCM (MC MG) and the corresponding lipid suspensions (14) as well as an aqueous suspension previously 
reported (14) (reanalysed with the intravenous data obtained in the present study). All oral parameters were obtained at a nilotinib dose of  
20 mg/kg and n = 5. Pharmacokinetic parameters of an intravenous formulation were obtained with a nilotinib dose of 2.5 mg/kg and n = 6. All 
studies were performed in male Sprague-Dawley rats. MRT, MAT and tmax given as median (range), all other parameters as mean ± SD. 
Pharmacokinetic parameters 
  cmax [µg/mL] 
tmax [h] 
(range) 
AUC 0-inf. h 
[µg*h/mL] 
MRT [h] (range) MAT [h] (range) Fabs [%] 
Aq. susp. a) 2.65 ± 0.68 2 (2 - 4) 14.33 ± 3.71 4.14 (3.34 - 4.83) 2.49 (1.69 - 3.18) 12.90 ± 3.34 
Lipid susp.  
Olive oil (LC TG) a) 
0.61 ± 0.56 4 (2 - 6) 3.60 ±2.82 5.64 (4.42 - 6.42) 4.00 (2.78 - 4.77) 3.24 ± 2.54 
Aq. susp.,  
Olive oil (LC TG) 
(chase dosed) 
3.48 ± 0.65 6 (4 – 8) 24.57 ± 5.65 7.87 (5.80 - 7.87) 6.22 (4.16 - 6.29) 22.11 ± 5.08 
Lipid susp.  
Captex 1000 (MC TG) a) 
0.77 ± 0.35 6 (4 - 10) 5.10 ± 2.35 6.18 (5.34 - 9.62) 4.54 (3.70 - 7.97) 4.58 ± 2.12 
Aq. susp.,  
Captex 1000 (MC TG) 
(chase dosed) 
2.93 ± 1.09 8 (0.5 – 10) 18.86 ± 6.01 8.15 (5.47 - 8.72) 6.50 (3.82 - 7.07) 16.97 ± 5.41 
Lipid susp.  
Peceol (LC MG) a) 
2.80 ± 0.76 4 (4 - 6)  13.63 ± 2.70 5.29 (4.85 - 6.16) 3.64 (3.21 - 4.51) 12.26 ± 2.43 
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Aq. susp.,  
Peceol (LC MG) 
(chase dosed) 
4.12 ± 0.67 6 (2 - 8) 27.47 ± 3.22 7.25 (4.56 - 7.98) 5.60 (2.92 - 6.33) 24.72 ± 2.90 
Lipid susp.  
Capmul MCM (MC MG) 
a) 
1.32 ± 1.04 4 (1 - 6) 9.58 ± 5.50 5.78 (5.17 - 6.14) 4.13 (3.53 - 4.49) 8.62 ± 4.95 
Aq. susp.,  
Capmul MCM (MC MG) 
(chase dosed) 
1.76 ± 0.47 8 (4 - 10) 15.18 ± 6.05 7.35 (5.49 - 8.24) 5.70 (3.85 - 6.59) 13.66 ± 5.44 
intravenous  - - 
22.31 ± 4.50 b) 
5.56 ± 1.19 c) 
1.70 (1.19 - 2.39) - - 
a) Data was previously reported (14) and re-analysed using intravenous data in the present study. 
b) Dose [mg] corrected 




3.2 Chase dosing leads to higher increases in bioavailability 
The results of the chase dosing study conducted in the present work were compared to a 
previously published in vivo study in rats that investigated lipid suspensions for nilotinib (14). 
In both studies olive oil (LC TG), Captex 1000 (MC TG), Peceol (LC MG) and Capmul MCM 
(MC MG) were administered at the same dose and lipid volume. The previously reported 
aqueous and lipid nilotinib suspensions (14) were re-analysed using the intravenous data 
obtained in the present study. The absolute bioavailability (Fabs) is shown in Figure 3 and the 
pharmacokinetic parameters are summarised in Table 1. 
 
 
Fig. 3. In vivo absolute bioavailability of nilotinib co-administered with LC TG (olive oil), 
MC TG (Captex 1000), LC MG (Peceol) and MC MG (Capmul MCM) in male Sprague-
Dawley rats (grey bars) in comparison to an aqueous suspension (white bar) and the four 
corresponding lipid suspensions (checked bars) in male Sprague-Dawley rats, which were 




In comparison to the lipid suspensions (14) the chase dosing approach of LC MG, LC TG and 
MC TG resulted in a statistically significant increase in the absolute bioavailability (p ≤ 0.05). 
The largest increase was observed for LC TG, where the chase dosing increased the absolute 
bioavailability by approximately 22 %. This translates to a 6.8-fold increase in bioavailability, 
relative to the Fabs of 3 % for the LC TG suspension. For the MC TG and LC MG formulations, 
chase dosing increased bioavailability 3.7-fold and 2-fold, respectively, compared to the 
suspension approach. While MC MG displayed an increase of approximately 5 % (1.6-fold), 
the difference was not significant indicating that relative to this excipient, a lipid suspension 
approach already reached a reasonably high bioavailability. The rank order of bioavailability 
increases of the chase dosed formulations relative to the lipid suspensions (i.e. non chase dosed) 
was TG > MG (LC TG > MC TG > LC MG > MC MG). Therefore, the greatest impact of 
chase dosing was observed for the least dispersible formulations, when compared to the lipid 
suspensions. For more readily dispersible formulations, chase dosing offered a relatively lower 
increase. These findings supported the hypothesis from the previous study in that the lowest 
bioavailability was observed for the least dispersible formulations (14). 
 
In the chase dosing study, the pharmacokinetic evaluation showed that the nilotinib absorption 
was prolonged. Relative to the lipid suspensions, there was a trend towards a prolonged time 
to reach the maximum plasma concentration (tmax), mean absorption time (MAT) and mean 
residence time (MRT). A consistent increase of 2 h in tmax from lipid suspensions to chase 
dosing was observed for LC TG, LC MG and MC TG. The same observation was made for 
MAT and MRT with an increase of approximately 2 h when the lipid excipient was chase 
dosed. For the MC MG excipient an increase of 4 h was observed for tmax and an increase of  
2 h was observed for MRT, while MAT was only prolonged by 1 h. While these trends for 
prolonged absorption were not statistically significant, reflecting a high variability in rate of 
Page 18 
 
absorption in vivo, the data suggested that the prolonged absorption may be a factor in 
explaining the improved bioavailability for chase dosing.  
 
3.3 Deconvolution to explore differences in absorption 
To further investigate the absorption from the tested formulations deconvolution was 
performed according to Langenbucher and Mysicka as described above (18). Using a numerical 
deconvolution technique, information about the in vivo drug absorption as a function of time 
was obtained. Deconvolution was calculated up to 8 h, which was the last plasma concentration 
within the limits of quantification of the bioanalysis. Normally, the cumulative integral for the 
last time point is set to 100 % drug absorbed (18, 19). Additionally, in this study, the cumulative 
integral for the last time point was set equal to the absolute bioavailability, as this approach 
provided insights on the extent and kinetics of the drug absorption process. The results of the 
deconvolution for the aqueous suspension, chase dosing and lipid suspensions of LC TG,  
LC MG, MC TG and MC MG, respectively, are shown in Figure 4. Additionally, Table 2 
presents a summary of the time needed to absorb 25 % and 50 % of the maximum absorbed 





Fig. 4. Numerical deconvolution of the aqueous suspension (dotted line, no symbol), chase 
dosing (open symbol) and the lipid suspensions (filled symbol) for LC MG [Peceol] (●),  
LC TG [Olive oil] (■), MC MG [Capmul MCM] (▲) and MC TG [Captex 1000] (▼). On the 
left absolute bioavailability was set as maximum drug released and absorbed, on the right 
maximum drug absorption was set to 100 % (mean ± SD, n = 5). 
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All chase dosed excipients increased the absorption rate of nilotinib in vivo compared to the 
lipid suspensions between 4 and 8 h. The rate of absorption from the LC TG, MC TG and  
MC MG suspensions were linear from 0 – 8 h. While for LC MG suspension a linear rate of 
absorption was observed in the first 2 h after administration, the absorption rate increased 
between 2 and 4 h. In case of the chase dosed formulations, the absorption rate was lower 
compared to the lipid suspensions up to 4 h post-dosing. However, the rate of absorption 
increased between 4 and 8 h, which was in agreement with the observation of a longer MAT. 
This increased absorption rate was also evident in the absorbed extent of nilotinib, which 
distinctly increased 4 h post-dosing. Thus, the apparently slower initial absorption rate did not 
translate to an overall lower amount of nilotinib being absorbed. For example, in the case of 
LC MG the higher absorption rate for the lipid suspension between 2 and 4 h resulted in the 




Table II Time to absorb 25 % and 50 % of the total fraction of absorbed drug for both lipid 
suspensions and chase dosed excipients with LC TG [olive oil], MC TG [Captex 1000],  
LC MG [Peceol] and MC MG [Capmul MCM] (mean ± SD, n = 5). 
Time to absorb 25 % of the drug [h] 
 
lipid suspension chase dosed 
LC TG 2.68 ± 0.78 3.97 ± 0.87 
MC TG 2.92 ± 0.70 3.94 ± 1.46 
LC MG 2.58 ± 0.39 3.49 ± 1.40 
MC MG 2.20 ± 0.38 3.44 ± 1.00 
Aq. susp. 1.24 ± 0.29 
Time to absorb 50 % of the drug [h] 
LC TG 3.99 ± 0.97 5.26 ± 0.71 
MC TG 4.57 ± 0.69 5.29 ± 0.99 
LC MG 3.28 ± 0.96 4.89 ± 1.22 
MC MG 4.00 ± 0.47 4.97 ± 0.80 
Aq. susp. 2.50 ± 0.43 
 
In contrast to the LBFs, where 50 % of drug was absorbed after 4 h, for the aqueous suspension 
the majority of drug was absorbed within the first 4 h. Within the first 4 h the aqueous 
suspension showed an absorption of approximately 10 % of the administered dose, which 
translates to approximately 77 % of the maximum absorbed amount. The remaining 3 % of the 
administered dose were absorbed between 4 and 8 h. In addition, the rate of absorption was 





LBFs have numerous biopharmaceutical benefits including the delivery of dissolved drug, a 
potential to promote lymphatic transport, improved intestinal permeability and most 
importantly an increased extent of in vivo solubilisation upon luminal dispersion and digestion 
of the formulation (3, 4). Many of the benefits of lipids in bio-enabling formulations are 
commonly demonstrated with drugs displaying high lipophilicity, i.e. ‘grease ball’ molecules, 
where the dose is soluble in the lipid vehicle to form a lipid solution. It has been reported that 
as a rule of thumb for a LBF approach a drug candidate should have a logP > 2 (23) and a 
melting point < 150 ⁰C (5). However, it is increasingly recognised that the hydrophobic 
characteristics of the drug merit consideration (24). For example, it has been reported that drugs 
with a melting point > 150 ⁰C may be less suited for formulation as lipid formulations, due to 
a high crystal lattice energy, which can lead to dose loading limitations in LBF (5). However, 
the merits of a LBF approach for drugs displaying both high hydrophobic and high lipophilic 
properties, may be theoretically limited due to the inability to dissolve drug in a reasonable 
lipid volume of the final dosage form. It remains unclear whether the additional 
biopharmaceutical benefits of lipid excipients for highly lipophilic drugs (e.g. in vivo 
solubilisation in post-digestive micellar fluids and/or increased permeability) may still lead to 
improved bioavailability. Therefore, for brick dust drugs, strategies focused on increasing dose 
loading in the lipid formulation have been reported such as supersaturated LBF (25, 26) or a 
lipophilic salt approach (6). Alternatively, the potential to administer a drug as a lipid 
suspension has been explored as a bio-enabling approach (8, 9, 14).  
 
Nilotinib, a tyrosine kinase inhibitor used in the treatment of leukaemia that was licenced in 
2007, shows a high lipophilicity (logP 4.95), but also a pronounced hydrophobicity. 
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Additionally, nilotinib showed a positive food effect (82 % increase in AUC after a high fat 
meal (27)) indicating a benefit from lipid excipients. For this high logP and melting point drug, 
solubility in lipid excipients was reported to be low (14). We have previously applied a lipid 
suspension approach to assess the impact of lipid excipients on the bioavailability of nilotinib 
in rats. However, despite high lipophilicity and a pronounced food effect, lipid suspensions 
based on MC and LC excipients did surprisingly not increase the bioavailability of nilotinib 
relative to an aqueous suspension. In the case of the TG formulations, bioavailability was even 
significantly reduced compared to an aqueous suspension (14). We hypothesised that the 
nilotinib particles were entrapped in the lipid excipient so that poor dispersion and a remaining 
lipid film on the particulate surface would kinetically hinder a favourable solubilization 
interaction with bile salts, phospholipids and other post-digestive components. Thus, a 
separation of drug and lipid excipient by chase dosing, i.e. a concomitant administration of a 
lipid, could prevent an entrapment and harness the aforementioned other in vivo benefits of 
lipid excipients.  
 
In comparison to the lipid suspension results (14), the chase dosing resulted in a significant 
increase in nilotinib bioavailability for LC TG (7-fold), MC TG (4-fold) and LC MG (2-fold) 
(p < 0.05). The highest increase in bioavailability between the lipid suspensions and the chase 
dosing was observed for the TG formulations, whereas in the case of the MG formulations the 
difference was low or indeed in the case of MC MG no difference was observed. Therefore, in 
the case of poorly dispersible formulations chase dosing of the drug with the LBF is preferred 
to prevent a masking of the bio-enabling effects. In fact, the drug load in the formulation and 
the solubility in the lipid excipient was not limiting the bioavailability once the formulation 
was chase dosed. The chase dosing also confirmed the previously hypothesized hampered 
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dissolution due to an entrapment of the nilotinib particles by the vehicle of the lipid suspensions 
(14).  
 
Chase dosing of the LBFs enhanced the bioavailability of nilotinib compared to the aqueous 
suspension and was in good agreement with previously published data (10, 11, 16). An 
improved bioavailability was reported for the co-administration of danazol (in rats), cinnarizine 
(in rats and humans), halofantrine (in rats) and carvedilol (in dogs) with different lipid 
excipients (10, 11, 16). The in vivo results also matched with the previously reported nilotinib 
solubility data in the post digestive state. Compared to fasted state simulated intestinal fluid 
(FaSSIF) the simulated LC TG and MC TG post digestion media had an approximately 17- and 
22-fold higher solubilisation capacity indicating that digestion was vital for an increased 
solubilisation capacity. Also, Kaukonen et al. showed that the exposure to post digestive 
products for highly hydrophobic drugs was of importance, because the solubilizing capacity of 
the post digestion phase was much higher compared to the drug that could be dissolved in the 
lipid excipient (28). Therefore, a rapid in vitro screening tool with simulated post digestive 
media could be helpful in early screenings as a model to predict a higher in vivo exposure by 
co-administering lipids.  
 
While the co-administration of LC based LBFs showed a statistically significant 2-fold increase 
compared to an aqueous suspension (p < 0.05), the MC based LBFs did not result in an 
increased bioavailability relative to the aqueous suspension. This fatty acid chain length effect 
was unexpected for nilotinib due to a higher solubility in MC dispersions pre- and post-
digestion compared to LC using simulated post-digestive media and in vitro lipolysis (14). 
However, the results of this study were in good agreement with previously reported effects that 
long chain fatty acids (digestion products of tri- and diglycerides) with a chain length of C12 
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or higher are able to increase cholecystokinin (CCK) plasma concentrations in humans (20, 
29). A similar effect of fatty acids with a chain length of C12 or higher was demonstrated in 
vitro using the mouse cell line STC-1, which is able to release CCK (21). Especially in the 
present study, where a lipid load of 2 mL/kg was used (resulting in approximately  
0.23 – 0.57 mol/L free fatty acids released upon digestion, depending on the available 
gastrointestinal volume), a stimulation of CCK was likely. CCK is a peptide hormone of the 
gastrointestinal tract, which stimulates the release of digestive enzymes and bile, which may 
increase the solubilisation of poorly water-soluble drugs in the intestinal fluids. In the case of 
nilotinib, an increased solubility was observed in the presence of higher bile salt concentrations 
in fed state simulated intestinal fluid (FeSSIF) (3.2 ± 0.1 µg/mL) when compared to FaSSIF 
(0.3 ± 0.03 µg/mL) (14). The MC excipients in the present study had a chain length of C8 and 
C10 and were not suspected to increase CCK plasma levels, which may explain the observed 
differences between MC and LC based excipients in vivo. In addition, the results in this study 
are in line with previous reports for LC based LBFs (Labrafil) that were co-administrated with 
danazol and cinnarizine. Compared to an aqueous suspension the co-administration for both 
drugs showed a 2-fold increase in bioavailability in rats (10). It is also interesting to note that 
nilotinib displayed a pronounced increase in bioavailability in the fed state in humans, and 
while the possible reasons for this are varied, this study suggested that dietary LC lipids may 
have a role in the improved bioavailability in the post prandial state.  
 
The results from deconvolution showed that the absorption of nilotinib from LBF suspensions 
appeared slower with less than 1 % of the total administered dose absorbed after 1 h. These 
results were in agreement with the in vitro lipolysis results reported for the lipid suspension 
study, where the total drug amount was below 1.1 % after 60 min of lipolysis (14). Also, the 
chase dosed LBFs showed a slow absorption with a total amount absorbed < 1 % after 1 h. 
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However, the deconvolution further showed a trend that the absorption from the chase dosed 
LBFs was prolonged. In the case of chase dosing, the initial 25 % and 50 % of nilotinib in the 
plasma was absorbed approximately 1 h later when compared to the initial 25 % and 50 % of 
nilotinib in plasma from the corresponding lipid suspensions. This kinetic advantage of the 
lipid suspensions did not result in an enhanced in vivo performance, but rather a similar or 
significantly decreased bioavailability. This difference most likely arose as a result of a 
decreased release of nilotinib from the LBF suspensions due to the compound’s high 
lipophilicity. The previously reported greater wettability of nilotinib crystals by lipid vehicles 
compared to aqueous vehicles suggested pronounced hydrophobic interactions between the 
lipids and nilotinib crystals (14). We hypothesised that these interactions favoured the 
formation of a lipid film around the nilotinib crystals, which remained intact even after 
dispersion in aqueous media and during the initial phases of digestion, and hence may be the 
most important contributing factor to the poor in vivo performance of the lipid suspensions. 
 
Administering LBFs resulted in a delayed absorption relative to the aqueous suspension. This 
was also evident by a longer tmax and MAT for the LBFs. A reason for the delayed absorption 
with lipid excipients may be the delayed gastric emptying. It was reported that the half-life 
(t1/2) of gastric emptying was approximately 77 min after a high caloric liquid meal in rats (30). 
Lipid excipients mimic fed state conditions (31) and may have delayed the gastric emptying 
when compared to the aqueous suspension, which should not affect gastric emptying. An 
additional factor contributing to a slower initial absorption may be digestion of the lipid 
excipients. This was especially prominent for the co-administered LBFs with LC TG, LC MG 
and MC TG. Despite the delayed initial absorption, over the next 4 h, extensive absorption was 
observed, which resulted in an overall increase in bioavailability compared to the aqueous 
suspension. This suggested that the access to post-digestive products of the lipid excipients as 
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well as to bile salts and phospholipids was more readily available for the chase dosed LBFs. It 
seemed that the MC MG was not able to generate a solubility increasing environment, which 
in part may be due to a very rapid digestion (14) and subsequent absorption of the excipient 
resulting in the same performance as the aqueous suspension.  
 
5 Conclusion 
The present study investigated the potential merits of lipid excipients to increase bioavailability 
of nilotinib, a ‘brick dust’ drug, by applying a chase dosing approach. Chase dosing of LBF 
was found to increase the bioavailability by up to 7-fold compared to the individual lipid 
suspensions. Also using this chase dosing approach, a significant bio-enabling effect of LC was 
observed with a 2-fold increased exposure compared to a non-lipid aqueous suspension. This 
study showed that the drug load in the lipid formulations may not be limiting in the context of 
the bio-enabling benefits of LBFs. The in vivo study also revealed that LC excipients performed 
better than MC excipients. Additionally, the study confirmed that dosing lipid suspensions of 
poorly dispersible LBF excipients like TGs should be avoided, whereas chase dosing of lipid 
excipients appears to be a viable approach to (a) explore the bio-enabling effects of lipid 
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